Rigel Pharmaceuticals

RIGL

Market cap $598M

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026.

Rigel Pharmaceuticals RIGL had an encouraging year in 2025. The company is yet to report its fourth-quarter and full-year 2025 results, but preliminary figures released last month point to another strong finish — driven primarily by the lead marketed drug Tavalisse.

Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to sustained momentum.

SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P.

Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.

Rigel Pharmaceuticals has benefitted from Tavalisse's sustained outperformance, driving increasing net income and attractive valuation metrics. Gavreto's recent flat performance is offset by RIGL's overall drug portfolio momentum and cash position improvement. R289 could have potential in lower-risk myelodysplastic syndromes, and additional clinical data provides a 2026 catalyst.

Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million In the dose escalation phase of the Phase 1b study of R289 in patients with lower-risk MDS, R289 continues to be generally well tolerated. RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group Enrollment in the dose expansion phase of the Phase 1b study is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026 2026 Outlook: Rigel anticipates full-year total revenue of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year SOUTH SAN FRANCISCO, Calif.